On the afternoon of November 8, 2025, the First Meeting of the Ninth Council of the Shanghai Overseas Friendship Association (SOFA) and its 40th Anniversary Commemoration took place at the Shanghai World Expo Exhibition & Convention Center. The event brought together over 400 governing members and representatives from domestic and international standing governing organizations to jointly review the SOFA's 40 years of development and envisage the future of overseas Chinese affairs and friendship in the new era.
The leadership of the 9th Council of SOFA and the heads of its special committees were elected at the meeting.Mr.Chen Tong, Member of the Standing Committee of the CPC Shanghai Municipal Committee and Director General of the United Front Work Department, was elected the new President of SOFA. In his address, he emphasized that SOFA must embrace and implement the Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era. He also called for uniting patriotic individuals both at home and abroad, supporting national reunification, promoting mutual understanding between Chinese and foreign civilizations, and contributing to Shanghai's high-quality development.
Prof. Lu Jiade Elected Vice President of SOFA, Recognized for His Medical Expertise
At the meeting, Prof. Lu Jiade, Vice President of Heyou International Health System, Director of Oncology Center, and Director of Heyou Proton and Heavy Ion Center, was elected Vice President of the 9th Council of SOFA. This appointment recognizes his significant contributions and widespread influence in the international medical community.
Prof. Lu Jiade is seated at the podium.
Prof. Lu, an esteemed leader in radiation oncology, has been instrumental in advancing tumor radiotherapy, as well as proton and heavy ion therapy. He previously served as Vice Chairman for Research at the National University Hospital (NUH) in Singapore, Director of the Radiotherapy Center, and Executive Vice President of the Shanghai Proton and Heavy Ion Hospital. His election to SOFA underscores Shanghai's recognition of his role in driving international medical exchanges, technological innovation, and cross-border collaborations.
Expert Profile | Prof. Lu Jiade
Prof. Lu Jiade holds a PhD in Medicine and an MBA. He is a member of the Management Board of Heyou International Health System, Vice President of Heyou Hospital, Director of Oncology Center, and Director of the Heyou Proton and Heavy Ion Center. As an expert selected for China's national high-caliber talent recruitment program and chief scientist in the Ministry of Science and Technology's Key Research and Development Program, Prof. Lu has been a pioneering force in clinical practice, research, and education in international tumor radiotherapy. His work merges Eastern and Western medical expertise, with a broad strategic vision.
Prof. Lu obtained his PhD degree in Medicine from the State University of New York - University at Buffalo (UB) and an MBA degree from the University of California, Los Angeles (UCLA) and the National University of Singapore (NUS). He completed his radiation oncology training at Jackson Memorial Hospital and was certified by the American Board of Radiology (ABR) in 2001. He also received certification in radiation oncology in Singapore in 2002.
Prof. Lu has published over 100 research papers, commentaries, and review articles in SCI journals, which demonstrate his extensive influence in international radiation oncology. He serves on the editorial boards of several international medical journals. As a key figure in promoting international medical publishing, he has edited or translated over a dozen English-language textbooks and reference books in radiation oncology, including two internationally recognized academic series published by Springer Nature: Medical Radiology – Radiation Oncology, and Practical Guides in Radiation Oncology. In particular, the Chinese version of Practical Guides in Radiation Oncology, hailed as a "teaching model for standardization in radiation oncology," is widely used in radiation oncology residency training and standardized practice in China.
Prof. Lu currently serves as the Editor-in-Chief of the SCI journal Chinese Clinical Oncology, dedicated to advancing clinical cancer research in the Asia-Pacific region and fostering international academic dialogues. He served as a member of the Executive Committee of the Chinese Society of Clinical Oncology (CSCO). He was appointed as a strategic advisor by multiple international listed healthcare companies and scientific research institutions.
Prof. Lu is not only a clinical expert but also a medical educator, an advocate for international collaboration, and a systems integrator in oncology center development. He believes that exceptional cancer treatment combines cutting-edge technology with visionary leadership and a human-centered approach. Moving forward, he will continue to guide the Heyou Oncology Center in integrating frontier knowledge with clinical applications, advancing Chinese-foreign cooperation in cancer care and public health education.
Pooling Efforts for Shared Development
Looking ahead, Prof. Lu will leverage Heyou Oncology Center to strengthen in-depth exchanges and collaboration between Heyou International Health System and the global medical community. His efforts will facilitate the sharing of high-end medical resources and boost the international development of China's medical oncology.
